Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Unlike many of its peers, Roche AG is not interested in developing a specific partnering strategy for China or other emerging markets, according to Joe McCracken, Roche's global head of business development and licensing. Instead, the Swiss pharma relies on a single global strategy that includes China as a key player, the exec told PharmAsia News Oct. 11 during an interview on the sidelines of the first BIO China conference in Shanghai

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts